Results 171 to 180 of about 123,600 (352)

International multicentre evaluation of a new anti‐idiotypic anti‐daratumumab for resolving pre‐transfusion interferences

Vox Sanguinis, EarlyView.
Abstract Background and Objectives Daratumumab, a therapeutic human anti‐CD38 monoclonal antibody, improves multiple myeloma outcomes but interferes with pre‐transfusion testing by binding CD38 on reagent red blood cells (RBCs), potentially masking clinically significant alloantibodies.
Arnaud Reggiani, Sofia Lejon Crottet, Sophie Waldvogel, Charlotte Engström, Serelina Coluzzi, Antonella Matteocci, Janis R. Hamilton, Levent Tufan Kumas, Karen M. K. de Vooght, Jill R. Storry, Jennylyn Flores, Núria Nogués, Carlos Cotorruelo, Molly Rutherford, Eveline B. Nilsen, Monika Pelc‐Kłopotowska, Jolanta Korzeniowska, Alessandra Baffa, Inna Sareneva, Nor Hafizah Ahmad, Katarzyna Szczudlo, Athif Rahman, Laser Sanal, Lise Jørgensen, Karolina Majewska Rochowiak, Monika Salwierz, Elisaveta Grancharova, Bojana Zivkovic, Jessica Alvarez, Mareike Riedl, Achim Knappik   +30 more
wiley   +1 more source

Co-occurrence of High-Risk Myelodysplastic Syndrome With a Complex Karyotype/TP53 Mutation and IgG Lambda Monoclonal Gammopathy of Undetermined Significance [PDF]

Marwa Mir, Wajeeha Aiman, Esther Baah, Gunwant Guron, Hamid Shaaban   +4 more
openalex   +1 more source

Cognitive Functioning in Vorinostat‐Treated Pediatric and Young Adult Patients Over the First 180 Days After Hematopoietic Stem Cell Transplant

Pediatric Blood &Cancer, Volume 73, Issue 6, June 2026.
ABSTRACT Purpose Cognitive and psychological difficulties could negatively interfere with treatment adherence and quality of life before and after hematopoietic stem cell transplant (HSCT). Methods to mitigate these changes may have positive effects on treatment success.
Kristen L. Votruba, Michelle Rozwadowski, Thomas Braun, April Rahrig, Edward Peres, Kirsten M. Williams, Vanessa Fabrizio, Julie‐An Talano, Carrie L. Kitko, Nicolas Parnell, Pavan Reddy, Sung Won Choi   +11 more
wiley   +1 more source

TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes [PDF]

, 2016
et al,, Fronick, C. C., Fulton, R. S., Ley, T. J., Miller, C. A., O\u27Laughlin, M., Petti, A. A., Wartman, L. D., Wilson, R. K.   +8 more
core   +2 more sources

Isolated Isochromosome 17q in Myelodysplastic Syndromes with Pure Red Cell Aplasia and Basophilia

, 2012
Yumiko Inui, Katsuya Yamamoto, Atsuo Okamura, Kimikazu Yakushijin, Yoshitake Hayashi, Hiroshi Matsuoka, Hironobu Minami   +6 more
openalex   +2 more sources

Distinct Pattern of Atypical Megakaryocytes in VEXAS Syndrome

International Journal of Laboratory Hematology, EarlyView.
Andrew Y. Sung, Jackson W. Douglas, Olga K. Weinberg, Sharon K. Germans, Weina Chen   +4 more
wiley   +1 more source

Gemcitabine, Docetaxel, Melphalan, Carboplatin as Part of Sequential Cycles of High‐Dose Chemotherapy With Autologous Hematopoietic Stem‐Cell Rescue for Multiply Relapsed/Refractory Pediatric Germ Cell Tumors

Pediatric Blood &Cancer, Volume 73, Issue 6, June 2026.
ABSTRACT Although most malignant germ cell tumors (GCTs) are highly curable with cisplatin‐based therapy, options for patients with multiply relapsed/refractory disease remain limited. For this population, we report the first pediatric use of gemcitabine, docetaxel, melphalan, and carboplatin (GemDMC) as part of sequential cycles of high‐dose ...
Maria Frost, Olayinka Okeleji, Amr Elgehiny, Douglas Harrison, Cynthia Herzog, Jeremy Connors, Demetrios Petropoulos, Priti Tewari, Dristhi Ragoonanan, Yago Nieto, Irtiza N. Sheikh   +10 more
wiley   +1 more source

A Feline Case of Myelodysplastic Syndrome-Erythroblastic (MDS-Er)

, 1996
Tadashi MIYAMOTO, Hisae HACHIMURA, Michinobu NOGUCHI, Akiteru AMIMOTO   +3 more
openalex   +2 more sources

Cost-effectiveness analysis of azacitidine in the treatment of high-risk myelodysplastic syndromes in Spain [PDF]

, 2013
Carlos Crespo, E. Moreno, Jordi Sierra, S. Serip, Marta Rubio   +4 more
openalex   +1 more source

CPX‐351 in High‐Risk Relapsed Pediatric Acute Leukemia: Real‐World Phase 1 Data Establishing the FDA‐Approved Dose

Pediatric Blood &Cancer, Volume 73, Issue 6, June 2026.
ABSTRACT Background/Objectives Outcomes for pediatric relapsed/refractory (R/R) acute myeloid leukemia (AML) remain dismal. CPX‐351, a liposomal formulation of cytarabine and daunorubicin, may have less off‐target toxicities than traditional chemotherapies and has shown improved outcomes for adults with newly diagnosed therapy‐related AML.
Jonathan D. Bender, Lauren Pommert, Lori R. Backus, Andrea Bidwell, Courtney Blank, Erin H. Breese, Karen C. Burns, Adam Lane, Lynn H. Lee, Benjamin Mizukawa, Robin E. Norris, Maureen M. O'Brien, Daniel Peck, Christine Phillips, Thomas D. Ryan, Jennifer Young, Michael Absalon, John P. Perentesis   +17 more
wiley   +1 more source